ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,444Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 48

$558K Total Retail Price of All Prescriptions

Rank: 13 out of 48

810 Patients Receiving at Least One Drug in Part D
60%Patients 65 Years and Older
63% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Mississippi
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 810 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

37% of this provider’s 810 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

5% of this provider’s 4,769 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

15% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $145 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Mississippi
HYDROCODONE-ACETAMINOPHEN 1,475 531 S3 1 3
GABAPENTIN 551 348 2 1
DONEPEZIL HCL 403 374 3 2
AMITRIPTYLINE HCL 371 145 R 4 9
LYRICA 339 92 5 8
PAROXETINE HCL 289 199 6 39
ZONISAMIDE 281 79 7 19
SERTRALINE HCL 276 212 8 24
NAMENDA 254 235 9 4
ZOLPIDEM TARTRATE 238 69 10 18
PHENYTOIN SODIUM EXTENDED 233 94 11 12
TOPIRAMATE 226 48 12 7
CITALOPRAM HBR 214 132 13 15
TRAMADOL HCL 209 91 14 16
TRAZODONE HCL 197 59 15 23
CARISOPRODOL 187 21 R 16 21
CARBIDOPA-LEVODOPA 154 127 17 6
LEVETIRACETAM 153 59 18 5
OXYCODONE HCL-ACETAMINOPHEN 148 46 S2 19 57
CYCLOBENZAPRINE HCL 140 12 R 20 33
RISPERIDONE 138 95 21 47
CYMBALTA 136 31 22 17
NADOLOL 131 24 23 62
FLUOXETINE HCL 115 52 24 44
PROPRANOLOL HCL 111 80 25 27
OMEPRAZOLE 110 66 26 51
METHOCARBAMOL 105 19 R 27 54
DIVALPROEX SODIUM ER 102 40 28 43
PRIMIDONE 101 80 29 10
BUSPIRONE HCL 84 28 30 78
AMLODIPINE BESYLATE 81 73 31 59
ESCITALOPRAM OXALATE 80 43 32 41
LAMOTRIGINE 76 48 33 11
FUROSEMIDE 76 0 33 81
OXYCODONE-ACETAMINOPHEN 75 24 S2 35 82
TIZANIDINE HCL 75 0 35 14
ENDOCET 74 14 S2 37 84
PROMETHAZINE HCL 74 11 R 37 37
QUETIAPINE FUMARATE 70 43 39 30
MELOXICAM 69 35 40 32
DIVALPROEX SODIUM 65 47 41 20
VENLAFAXINE HCL 62 29 42 91
BUPROPION HCL 61 38 43 92
NORTRIPTYLINE HCL 53 0 44 35
LEVOTHYROXINE SODIUM 50 30 45 104
CARBAMAZEPINE 50 18 45 29
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 11, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.